242 related articles for article (PubMed ID: 36244674)
1. Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI.
Naik S; Burk KS; Budiawan E; Lacson R; Lee LK; Fennessy FM; Tempany C; Cole AP; Trinh QD; Kibel AS; Khorasani R
J Am Coll Radiol; 2022 Dec; 19(12):1312-1321. PubMed ID: 36244674
[TBL] [Abstract][Full Text] [Related]
2. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
4. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
5. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
8. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Pellegrino F; Stabile A; Mazzone E; Sorce G; Barletta F; De Angelis M; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Prostate; 2022 Sep; 82(12):1170-1175. PubMed ID: 35538401
[TBL] [Abstract][Full Text] [Related]
9. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
12. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
13. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
15. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
16. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
Singh S; Rogers H; Kanber B; Clemente J; Pye H; Johnston EW; Parry T; Grey A; Dinneen E; Shaw G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Giganti F; Atkinson D; Moore CM; Whitaker HC; Alexander DC; Panagiotaki E; Punwani S
Radiology; 2022 Dec; 305(3):623-630. PubMed ID: 35916679
[TBL] [Abstract][Full Text] [Related]
17. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
18. Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
Krausewitz P; Büttner T; von Danwitz M; Weiten R; Cox A; Klümper N; Stein J; Luetkens J; Kristiansen G; Ritter M; Ellinger J
BMC Urol; 2024 Mar; 24(1):71. PubMed ID: 38532370
[TBL] [Abstract][Full Text] [Related]
19. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
20. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
